Schott Pharma USA, a US-based subsidiary of German firm Schott Pharma, plans to build a new syringe production facility in the US state of North Carolina this year.

Schott Pharma will invest $371m in the project, located in Wilson. The facility will generate pre-fillable polymer and glass syringes for pharmaceutical and biotech companies, to help increase the U.S. supply of injectable vaccines and other therapeutic treatments, such as for diabetes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Andreas Reisse, CEO Schott Pharma, said: “The impact of this facility will go far beyond local job creation in North Carolina and will relieve stress on the entire pharmaceutical industry supply chain.”

SCHOTT Pharma USA was enticed to Wilson County by almost $23m in incentives from state and local governments, including monetary, infrastructure, and training grants. An economic incentives committee is offering cash payments of nearly $5m, but they depend on the company meeting job-creation and investment thresholds.

SCHOTT Pharma employs over 4,600 workers worldwide. The facility is expected to commence operations in 2027.